Table 1. Inhibitory effect of EGCG on LPS-induced TNF-α, VEGF, MCP-1 and NO production in HRECs.
| Groups | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| LPS (250 ng/mL) | + | + | + | + | + | + | -- |
| EGCG (µmol/L) | 100 | 50 | 25 | 12.5 | 6.25 | 0 | 0 |
| VEGF (pg/mL) | 75.7±14.6b | 99.3±15.7b | 145. 7±15.6b | 206.0±16.1 | 252.3±17.4 | 309.7±57.7d | 45.7±9.3 |
| NO (µmol/L) | 8.9±1.1b | 16.1±1.8b | 24.6±2.9b | 34.9±2.3 | 44.1±3.6 | 43.7±7.7d | 3.9±0.6 |
| MCP-1 (pg/mL) | 261.0±30.3b | 375.3±30.2b | 613.0±60.6b | 774.0±36.7 | 926.0±99.5 | 862.7±47.5d | 143.7±16.6 |
| TNF-α (pg/mL) | 49.7±12.0b | 52.7±17.6b | 81.0±12.7b | 110.7±13.5 | 125.7±11.7 | 133.0±12.5d | 29.7±6.0 |
HRECs were pre-treated with EGCG (0-100 µmol/L) for 2h followed by incubation with or without of LPS (250 ng/mL) for 24h. Levels of TNF-α, VEGF, MCP-1 and NO were determined by ELISA and Griess assay. Data represent Mean±SEM (n=3). bP<0.01 vs LPS alone (group 6); dP<0.01 vs control group (group 7).